Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Swine flu vaccine is a peptide-based vaccine candidate developed by Youfeng Biotechnology for the prevention of H1N1 influenza (swine flu). The vaccine utilizes the proprietary Ii-Key peptide technology, which involves linking an antigenic epitope from the H1N1 virus to a specific four-amino acid sequence (the Ii-Key). This modification allows the peptide to bypass traditional intracellular processing and bind directly to the MHC class II molecules on the surface of antigen-presenting cells. This mechanism is designed to significantly enhance the potency of the T-helper cell response and overall immunogenicity compared to standard peptide vaccines. The candidate has completed Phase 1 clinical testing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on swine flu vaccine (Youfeng Biotechnology).